Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Inclusion Criteria:

• Male or female subjects, age 18 or older who have signed the informed consent form

• Must have a qualifying community-acquired bacterial pneumonia

• Subjects must not be pregnant or nursing at the time of enrollment

• Must agree to a reliable method of birth control during the study and for 30 daysfollowing the last dose of study drug

Exclusion Criteria:

• Known or suspected hospital-acquired pneumonia

• Confirmed or suspected SARS-CoV-2 infection

• Evidence of significant immunological disease

• Has a life expectancy of less than or equal to 3 months or any concomitant conditionthat is likely to interfere with evaluation of the response of the infection understudy, determination of AEs, or completion of the expected course of treatment

• Has a history of contraindications, hypersensitivity, or allergic reaction to anytetracycline or fluoroquinolone antibiotic

• Has received an investigational drug within the past 30 days